AstraZeneca Pharma India growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+32.6%+32.5%+29.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+3.2%+37.7%+11.7%
+9.1%+26.2%+13.9%
+62.0%−28.3%+62.7%
+62.0%−28.3%+62.6%
+31.0%+40.8%+9.5%
+13.3%+8.2%+20.9%
−123.2%−29.4%+58.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ASTRAZEN₹6,299.00

AstraZeneca Pharma India Limited

· Pharma & Health
₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹15,748 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+29.2+32.5+32.6—
EBITDA Growth—+11.7+37.7+3.2—
EBIT Growth—+13.9+26.2+9.1—
Net Income Growth—+62.7-28.3+62.0—
EPS Growth—+62.6-28.3+62.0—
Total Assets Growth—+9.5+40.8+31.0—
Total Equity Growth—+20.9+8.2+13.3—
Cash from Operations Growth—+58.7-29.4-123.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.